Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 6 of 12
Jun 6, 2026Presented at the American Diabetes Association conference, Eli Lilly’s retatrutide continues to show promise as a next-generation obesity therapy, highlighting advancements in efficacy and patient safety. The new data provide critical insights into how this triple agonist could shape future obesity management.
Dr. Priya Nandakumar
Jun 5, 2026With breast cancer remaining a leading cause of mortality worldwide, Ona Therapeutics' recent funding milestone highlights the critical need for novel therapeutic strategies such as their unique antibody drug conjugates (ADCs). This post delves into the technology, challenges in ADC development, clinical prospects, and broader implications for oncology.
Dr. Alex Morgan
Jun 4, 2026Revolution Medicines has developed a promising new drug for pancreatic cancer, generating significant interest within the medical community. However, this growing demand poses challenges in ensuring sufficient supply and equitable patient access, underscoring the complexities in bringing breakthrough cancer treatments to market.
Michael Torres
Jun 4, 2026Scientists have identified a novel reservoir where HIV can hide within the body, complicating efforts to eradicate the virus. This discovery opens new avenues for research on HIV persistence and potential therapeutic interventions.
Emily Carter
Jun 2, 2026Emerging radiopharmaceuticals are increasingly becoming a focus in biotech, offering targeted therapeutic options that may improve the treatment landscape for complex diseases. Recent data indicate promise in the post-Pluvicto setting, underscoring the evolving opportunities in this field.
Jonathan Blake
Jun 2, 2026The absence of licensed vaccines for the present Ebola virus variant has spurred urgent public health efforts. Collaborations including Moderna and CEPI, backed by $62 million in funding, are driving fast-track clinical studies to identify viable vaccine solutions rapidly. These efforts may significantly shape future epidemic responses and vaccine preparedness.
Daniel Cho
Jun 1, 2026Recent clinical data presented at the American Society of Clinical Oncology highlight linvoseltamab’s high efficacy in inducing complete responses in a majority of patients with light chain amyloidosis, a disease with previously limited treatment options. This article explores the drug’s mechanism, trial outcomes, and broader implications for rare disease therapeutics.
Daniel Cho
May 31, 2026Cancer immunotherapy has revolutionized oncology care, yet high costs limit access in low-income settings. Recent clinical trial results showcase the promise of ultra-low dose strategies to extend survival in head and neck squamous cell carcinoma, opening new possibilities for global cancer treatment equity.
Jonathan Blake
May 31, 2026Pancreatic cancer is urgently in need of new therapies due to its poor prognosis and resistance to treatment. At ASCO 2026, data emerged from Revolution Medicines demonstrating that daraxonrasib successfully targets a previously 'undruggable' molecule involved in pancreatic cancer progression. These results could herald a new era in managing a notoriously difficult cancer type.
Daniel Cho
May 29, 2026In a critical advancement for patients suffering from blastic plasmacytoid dendritic cell neoplasm, AbbVie has gained FDA approval for Decnupaz, the first antibody-drug conjugate therapy indicated for this ultra-rare malignancy. This milestone highlights the continuing importance of targeted biopharmaceutical approaches to treat challenging hematologic cancers.
Sophia Reynolds
May 25, 2026Eli Lilly has announced promising early results from a clinical trial using its Verve’s gene-editing therapy. The phase 1 study revealed that high-dose treatment significantly reduced cholesterol levels, pointing to new possibilities in gene-based cardiovascular interventions.
Dr. Alex Morgan
May 21, 2026This post dives into the dynamics of Germany's biotech capital, featuring insights from key venture capital experts about the ecosystem's strengths, challenges, and the strategic steps necessary to bolster innovation while maintaining a European base for growth.
Dr. Alex MorganMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.